third-party technology solutions to develop product candidates with the potential for significant target engagement while maintaining favorable pharmacologic properties.Step 3—Clinical Trial and Regulatory ExecutionOur clinical development strategy employs a stepwise approach designed to identify response signals early in development and reduce
drivers.•Work with experienced third parties in the field of diagnostics.•Conduct international clinical and regulatory programs to support our global approval and commercialization strategy.•Leverage our business model to maximize the value of our current external collaboration while remaining open to additional
we or our collaborators are unable to successfully develop and commercialize LOXO-101 or experience significant delays in doing so, our business will be materially harmed.•Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates.
In addition, we expect to receive net proceeds of $2.8 million from the sale of shares of common stock to NEA in the concurrent private placement, after deducting estimated
expansion trial for LOXO-101, research and development, advancement of preclinical product candidates and working capital and other general corporate purposes, including costs associated with being a public company.
as otherwise indicated, all information in this prospectus assumes:•a 1.5625-for-1 forward stock split of our outstanding common stock that was effected on July 21, 2014;•the effectiveness of our restated certificate of incorporation in connection with the completion of this offering;•no exercise of outstanding stock options subsequent to March 31, 2014; and•no exercise of the underwriters' over-allotment option.9Table of ContentsSUMMARY FINANCIAL DATAThe summary statements of operations data presented below for the period from May 9, 2013 (date of inception) to
common stock as of the beginning of the period presented or actual issuance date, if later and does not include any shares issued subsequent to March 31, 2014.10Table of ContentsAs of March 31, 2014ActualPro Forma(1)Pro Forma asAdjusted(2)(unaudited)(In thousands)Balance Sheet Data:Cash and cash equivalents$26,933$55,322$109,022Total assets27,44555,813109,513Total liabilities596596596Deficit accumulated during the development stage(13,192)(13,192)(13,192)Total stockholders' (deficit) equity(13,005)55,217108,917(1)Pro
in-license products or technologies;•our ability to establish additional discovery collaborations on favorable terms, if at all;•the costs, timing and outcome of regulatory review of our product candidates;13Table of Contents•the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for
For example, to execute our business plan, we will need to successfully:•execute LOXO-101 development activities;•obtain required regulatory approvals for the development and commercialization of LOXO-101;•maintain, leverage and expand our intellectual property portfolio;•build and maintain robust sales, distribution and marketing capabilities, either on our own or in collaboration with
strategic partners;•gain market acceptance for LOXO-101;•develop and maintain any strategic relationships we elect to enter into, including our collaboration with Array; and•manage our spending as costs and expenses increase due to drug discovery, preclinical development, clinical trials,
we are unsuccessful in accomplishing these objectives, we may not be able to successfully develop and commercialize LOXO-101, and our business will suffer.Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates.
approval of our product candidates, including:•unforeseen safety issues or adverse side effects;•failure of our companion diagnostics in identifying patients;•modifications to protocols of our clinical trials resulting from FDA or institutional review board, or IRB, decisions; and•ambiguous or negative interim results of our clinical trials, or results that are inconsistent with earlier results.Clinical drug development involves a lengthy and expensive process, with an uncertain outcome.
delays, requirements to conduct additional clinical studies and increased expenses associated with the services of our clinical research organizations ("CROs") and other third parties;•clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the
our product candidates, if approved for commercial sale, will depend on a number of factors, including:•the efficacy and safety and potential advantages and disadvantages compared to alternative treatments;•our ability to offer our products for sale at competitive prices;•the convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;•the strength of our marketing and distribution support;•the availability of third-party coverage and adequate reimbursement, including patient cost-sharing programs such as
the further development of our product candidates could be delayed.Risks Related to Our Common Stock and This OfferingAfter this offering and the concurrent private placement, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have
the difference between our pro forma net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price.Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans or otherwise, could result in dilution to
The market price for our common stock may be influenced by many factors, including:•the success of competitive products or technologies;•results of clinical trials of our product candidates or those of our competitors;•events affecting our collaboration partners, including Array;•regulatory or legal developments in the United States and other countries;•developments or disputes concerning patent applications, issued patents or other proprietary rights;•the recruitment or departure of key personnel;•the level of expenses related to any of our product candidates or clinical development programs;42Table of Contents•the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities